<DOC>
	<DOCNO>NCT01005069</DOCNO>
	<brief_summary>The purpose study investigate clinical efficacy safety DLBS 32 management subject type-II-diabetes mellitus determine minimal effective dose DLBS 32 subject type-II-diabetes mellitus .</brief_summary>
	<brief_title>Efficacy DLBS-32 Subjects With Type-II Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Fasting capillary blood glucose 127249 mg/dL screen BMI &gt; = 18.5 kg/m^2 waist circumference &gt; = 90 cm ( male ) &gt; = 80 cm ( female ) Normal liver function Normal renal function OHAnaive typeIIdiabetic patient Symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia Uncontrolled hypertension History current treatment insulin Current treatment systemic corticosteroid herbal ( alternative ) medicine History renal and/or liver disease Pregnant breast feeding female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>DLBS-32</keyword>
	<keyword>fast plasma glucose</keyword>
	<keyword>insulin resistance</keyword>
</DOC>